MIRM
Mirum Pharmaceuticals, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.+553.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MIRM vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.55B
5Y Perf.-62.1%
MIRM vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MIRM | RARE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $5.53B | $2.55B |
| Revenue (TTM) | $410M | $669M |
| Net Income (TTM) | $-799M | $-609M |
| Gross Margin | -103.2% | 83.6% |
| Operating Margin | -194.4% | -83.9% |
| Total Debt | $319M | $1.28B |
| Cash & Equiv. | $297M | $434M |
MIRM vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MIRM
RARE
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Mirum Pharmaceutica… (MIRM) | 100 | 653.3 | +553.3% |
| Ultragenyx Pharmace… (RARE) | 100 | 37.9 | -62.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MIRM vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MIRM leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Ultragenyx Pharmaceutical Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
MIRM
Mirum Pharmaceuticals, Inc.
The Income Pick
MIRM carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 1.02
- Rev growth 54.7%, EPS growth 74.6%, 3Y rev CAGR 89.1%
- 7.3% 10Y total return vs RARE's -58.9%
Best for: income & stability and growth exposure
RARE
Ultragenyx Pharmaceutical Inc.
The Quality Compounder
RARE is the clearest fit if your priority is quality and efficiency.
- -91.0% margin vs MIRM's -195.0%
- -45.8% ROA vs MIRM's -98.5%, ROIC -89.4% vs -5.0%
Best for: quality and efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MIRM | 54.7% revenue growth vs RARE's 20.1% |
| Quality / Margins | RARE | -91.0% margin vs MIRM's -195.0% |
| Stability / Safety | MIRM | Beta 1.02 vs RARE's 1.42 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MIRM | +168.5% vs RARE's -26.0% |
| Efficiency (ROA) | RARE | -45.8% ROA vs MIRM's -98.5%, ROIC -89.4% vs -5.0% |
MIRM vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
MIRM vs RARE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMIRMLAGGINGRARE
RAREUltragenyx Pharmaceut…
1leads
MIRMMirum Pharmaceuticals…
3leads
6 Total Categories
CATEGORYLEADERvs RAREMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RARE5/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MIRM7/8
Total Returns1Y, 3Y, 5Y total returns with dividends
MIRM6/6
Risk & VolatilityBeta, volatility, and downside exposure
MIRM2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RARE leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
RARE is the larger business by revenue, generating $669M annually — 1.6x MIRM's $410M. RARE is the more profitable business, keeping -91.0% of every revenue dollar as net income compared to MIRM's -195.0%. On growth, RARE holds the edge at -2.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | MIRMMirum Pharmaceuti… | RAREUltragenyx Pharma… |
|---|---|---|
| RevenueTrailing 12 months | $410M | $669M |
| EBITDAEarnings before interest/tax | -$778M | -$536M |
| Net IncomeAfter-tax profit | -$799M | -$609M |
| Free Cash FlowCash after capex | -$173M | -$487M |
| Gross MarginGross profit ÷ Revenue | -103.2% | +83.6% |
| Operating MarginEBIT ÷ Revenue | -194.4% | -83.9% |
| Net MarginNet income ÷ Revenue | -195.0% | -91.0% |
| FCF MarginFCF ÷ Revenue | -42.1% | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -43.8% | -17.2% |
RARE leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
Evenly matched — MIRM and RARE each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | MIRMMirum Pharmaceuti… | RAREUltragenyx Pharma… |
|---|---|---|
| Market CapShares × price | $5.5B | $2.5B |
| Enterprise ValueMkt cap + debt − cash | $5.5B | $3.4B |
| Trailing P/EPrice ÷ TTM EPS | -234.21x | -4.45x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 2632.18x | — |
| Price / SalesMarket cap ÷ Revenue | 10.60x | 3.79x |
| Price / BookPrice ÷ Book value/share | 17.56x | — |
| Price / FCFMarket cap ÷ FCF | 100.70x | — |
Evenly matched — MIRM and RARE each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
MIRM leads this category, winning 7 of 8 comparable metrics.
Profitability & Efficiency
MIRM delivers a -2.9% return on equity — every $100 of shareholder capital generates $-3 in annual profit, vs $-6 for RARE. On the Piotroski fundamental quality scale (0–9), MIRM scores 6/9 vs RARE's 4/9, reflecting solid financial health.
| Metric | MIRMMirum Pharmaceuti… | RAREUltragenyx Pharma… |
|---|---|---|
| ROE (TTM)Return on equity | -2.9% | -6.1% |
| ROA (TTM)Return on assets | -98.5% | -45.8% |
| ROICReturn on invested capital | -5.0% | -89.4% |
| ROCEReturn on capital employed | -3.7% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 4 |
| Debt / EquityFinancial leverage | 1.02x | — |
| Net DebtTotal debt minus cash | $23M | $842M |
| Cash & Equiv.Liquid assets | $297M | $434M |
| Total DebtShort + long-term debt | $319M | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | -0.03x | -14.49x |
MIRM leads this category, winning 7 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
MIRM leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MIRM five years ago would be worth $62,192 today (with dividends reinvested), compared to $2,241 for RARE. Over the past 12 months, MIRM leads with a +168.5% total return vs RARE's -26.0%. The 3-year compound annual growth rate (CAGR) favors MIRM at 61.0% vs RARE's -18.0% — a key indicator of consistent wealth creation.
| Metric | MIRMMirum Pharmaceuti… | RAREUltragenyx Pharma… |
|---|---|---|
| YTD ReturnYear-to-date | +41.0% | +9.9% |
| 1-Year ReturnPast 12 months | +168.5% | -26.0% |
| 3-Year ReturnCumulative with dividends | +317.6% | -44.9% |
| 5-Year ReturnCumulative with dividends | +521.9% | -77.6% |
| 10-Year ReturnCumulative with dividends | +733.3% | -58.9% |
| CAGR (3Y)Annualised 3-year return | +61.0% | -18.0% |
MIRM leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
MIRM leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MIRM is the less volatile stock with a 1.02 beta — it tends to amplify market swings less than RARE's 1.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MIRM currently trades 99.6% from its 52-week high vs RARE's 61.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MIRMMirum Pharmaceuti… | RAREUltragenyx Pharma… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.02x | 1.42x |
| 52-Week HighHighest price in past year | $110.48 | $42.37 |
| 52-Week LowLowest price in past year | $40.00 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +99.6% | +61.2% |
| RSI (14)Momentum oscillator 0–100 | 69.1 | 61.0 |
| Avg Volume (50D)Average daily shares traded | 807K | 1.8M |
MIRM leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates MIRM as "Buy" and RARE as "Buy". Consensus price targets imply 98.6% upside for RARE (target: $52) vs 9.4% for MIRM (target: $120).
| Metric | MIRMMirum Pharmaceuti… | RAREUltragenyx Pharma… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $120.40 | $51.50 |
| # AnalystsCovering analysts | 18 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MIRM leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). RARE leads in 1 (Income & Cash Flow). 1 tied.
Best OverallMirum Pharmaceuticals, Inc. (MIRM)Leads 3 of 6 categories
Loading custom metrics...
MIRM vs RARE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MIRM or RARE a better buy right now?
For growth investors, Mirum Pharmaceuticals, Inc.
(MIRM) is the stronger pick with 54. 7% revenue growth year-over-year, versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). Analysts rate Mirum Pharmaceuticals, Inc. (MIRM) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MIRM or RARE?
Over the past 5 years, Mirum Pharmaceuticals, Inc.
(MIRM) delivered a total return of +521. 9%, compared to -77. 6% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: MIRM returned +733. 3% versus RARE's -58. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MIRM or RARE?
By beta (market sensitivity over 5 years), Mirum Pharmaceuticals, Inc.
(MIRM) is the lower-risk stock at 1. 02β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 39% more volatile than MIRM relative to the S&P 500.
04Which is growing faster — MIRM or RARE?
By revenue growth (latest reported year), Mirum Pharmaceuticals, Inc.
(MIRM) is pulling ahead at 54. 7% versus 20. 1% for Ultragenyx Pharmaceutical Inc. (RARE). On earnings-per-share growth, the picture is similar: Mirum Pharmaceuticals, Inc. grew EPS 74. 6% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, MIRM leads at 89. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MIRM or RARE?
Mirum Pharmaceuticals, Inc.
(MIRM) is the more profitable company, earning -4. 5% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps -4. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MIRM leads at -4. 2% versus -79. 5% for RARE. At the gross margin level — before operating expenses — RARE leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MIRM or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MIRM or RARE better for a retirement portfolio?
For long-horizon retirement investors, Mirum Pharmaceuticals, Inc.
(MIRM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 02), +733. 3% 10Y return). Both have compounded well over 10 years (MIRM: +733. 3%, RARE: -58. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MIRM and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(MIRM: -100.0% · RARE: -2.4%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.